---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-23-000052"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T01:08:51.515449+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho preliminary Q3 revenue $738-744M; beats on early respiratory demand

## Summary
- Total revenue $738-744M vs prior expectations; non-respiratory $557-560M, respiratory $181-184M.
- Earlier-than-expected flu and COVID demand drove respiratory product sales higher in the quarter.
- Full-year 2023 guidance maintained: rev $2.88-3.08B, adj EPS $4.85-5.30, adj EBITDA $800-830M.
- All regions including China met or exceeded expectations; Q3 full results to be reported Nov 1, 2023.

## SEC filing metadata
- accession: 0001906324-23-000052
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/0001906324-23-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/qdel-20231012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-23-000052
- JSON: https://secwatch.observer/filing/0001906324-23-000052.json
- Plain text: https://secwatch.observer/filing/0001906324-23-000052.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported fiscal third quarter ended October 1, 2023 results: revenue $738 million to $744 million. Guidance reaffirmed.
  - Period: fiscal third quarter ended October 1, 2023
  - Revenue: $738 million to $744 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. Third Quarter 2023 Preliminary Unaudited Revenue Results • Total revenues of $738 million to $744 million; • Non-respiratory product revenue of $557 million to $560 million; and • Respiratory product revenue of $181 million to $184 million. “Our strong performance in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/0001906324-23-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.